Medications Development for the Treatment of Amphetamine and Amphetamine Like Related Disorders (R21) | Apply Online

Opportunity Summary:

The Medications Development for the Treatment of Amphetamine and Amphetamine Like Related Disorders (R21) opportunity (Funding Opportunity Number PA-07-334) is a National Institutes of Health grant announcement, led by the National Institute on Drug Abuse (NIDA), focused on accelerating early stage medication development research for amphetamine and amphetamine-like related disorders (ARDs). The central aim is to stimulate both preclinical and clinical studies that can identify promising medication candidates, evaluate their potential, and move them closer to becoming safe and effective treatments, with the highest priority placed on methamphetamine abuse and methamphetamine dependence. The announcement is grounded in the public health reality that, despite extensive harm linked to these substances, there are no broadly effective, FDA-approved pharmacological treatments specifically for ARDs, and research investment in medication development and long-term health effects has historically been limited.

The scope of disorders and substances covered is intentionally broad. Using the DSM-IV-TR framing referenced in the announcement, the program includes drugs with a substituted phenylethylamine structure such as amphetamine, dextroamphetamine, methamphetamine, and MDMA, while also including substances that may be structurally different but produce amphetamine-like effects. Examples listed include methylphenidate, certain appetite suppressants, and khat. This wide lens reflects how stimulant misuse and dependence can arise from multiple agents with similar central nervous system stimulant properties and similar patterns of addiction risk. The opportunity emphasizes that these drugs are highly addictive and commonly used through several routes of administration, including injection, snorting, smoking, and oral ingestion, which can influence both the intensity of effects and the medical complications that follow.

A major driver for this funding priority is methamphetamine specifically, described as a continuing and widespread public health concern across the United States. The announcement highlights methamphetamine's distinctive role in the domestic drug landscape: it is relatively easy to manufacture in clandestine laboratories using accessible retail materials, and it has been the most prevalent synthetic drug produced in the U.S. This combination of ease of production, high addictive potential, and broad distribution has helped the problem spread beyond its earlier concentration in the western U.S. to most major metropolitan areas nationwide. The program announcement uses this context to justify an urgent need for new medications that can reduce use, prevent relapse, and improve treatment outcomes for people with methamphetamine and related stimulant use disorders.

From a funding mechanics standpoint, this is an R21 mechanism, which generally supports exploratory or developmental research intended to generate early proof-of-concept data, novel approaches, or feasibility evidence that can justify larger follow-on studies. While the announcement does not specify dollar caps or project periods in the excerpt provided, the R21 format typically aligns with shorter, milestone-driven projects that test innovative medication development ideas rather than fully mature, large-scale clinical trials. The broader intent is to build a stronger pipeline of candidate treatments by encouraging creative, well-justified studies at stages where conventional funding may be harder to secure.

Administratively, the opportunity is categorized as a discretionary grant under CFDA 93.279 (Drug Abuse and Addiction Research Programs), with no cost sharing or matching requirement. It was originally posted March 22, 2007, and the listing notes multiple receipt dates rather than a single deadline, meaning applications were accepted on recurring cycles during the active period of the announcement. The archive date shown is June 7, 2010, indicating the specific announcement is no longer active in that form, though similar NIH/NIDA opportunities may exist under updated numbers and notices.

Eligibility is broad and includes many organization types: public and private institutions of higher education, nonprofits (including those without 501(c)(3) status), for-profit organizations other than small businesses, small businesses, state and local governments, independent school districts, special district governments, public housing authorities, and Native American tribal governments and tribal organizations. The eligibility section also notes that foreign institutions may apply, eligible federal agencies may apply, and faith-based or community-based organizations are eligible. This wide eligibility is designed to attract diverse research teams, including academic labs, clinical research centers, biotech and pharmaceutical developers, and community-linked organizations with the ability to recruit and study affected populations.

In practical terms, the opportunity is aimed at increasing the number and quality of medication development efforts targeting stimulant-related disorders, especially methamphetamine use disorder, by supporting innovative early stage research that can produce actionable findings. The announcement frames the problem as both urgent and underserved: stimulant addiction is widespread, methamphetamine is uniquely easy to produce and distribute domestically, and the field lacks effective pharmacological options. By encouraging exploratory preclinical and clinical work, NIDA sought to expand the scientific base needed to bring viable medication candidates forward into more advanced testing and, ultimately, into real-world treatment settings.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Development of Animal Models and Related Biological Materials For Research (R21)

Previous opportunity: Medications Development for the Treatment of Amphetamine and Amphetamine Like Related Disorders (R01)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 07 334

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 07 334) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 07 334", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.